Market Overview

Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories

Share:
Related ABT
10 Technical Levels Discussed On Monday's PreMarket Prep
Mid-Afternoon Market Update: Dow Gains 160 Points; Akari Therapeutics Shares Plummet
GSB Wealth Management, LLC Buys DNP Select Income Fund, DNP Select Income Fund, DowDuPont Inc, ... (GuruFocus)

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Morgan Stanley noted, “The most challenging quarter of the year is behind the company and we see clarity to acceleration ahead. Consensus under-appreciates margin momentum into 2H14 and 15'. As EPS and revenue move higher into 2Q, shares will follow. Reiterate our OW thesis and $45 target.”

Abbott Laboratories closed on Wednesday at $38.38.

Latest Ratings for ABT

DateFirmActionFromTo
Oct 2017BarclaysMaintainsOverweight
Oct 2017CitigroupMaintainsNeutral
Oct 2017Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!

Partner Center